Guadecitabine sodium
Based on 12 publication(s) in Google Scholar
Guadecitabine sodium (SGI-110 sodium) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
For research use only. We do not sell to patients.
- Purity: 99.97%
- CAS No.: 929904-85-8
- Formula: C18H23N9NaO10P
- Molecular Weight:579.39
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Guadecitabine sodium
More- Cancer Res. 2020 Jul 15;80(14):3046-3056. [Abstract]
- Mol Cell. 2022 Oct 20;82(20):3901-3918.e7. [Abstract]
- J Exp Clin Cancer Res. 2023 Mar 18;42(1):67. [Abstract]
- J Transl Med. 2024 Mar 1;22(1):223. [Abstract]
- Neoplasia. 2020 May 25;22(7):274-282. [Abstract]
- Epigenomes. 2021 Dec 14;5(4):27. [Abstract]
- JID Innov. 2024 Oct 16;5(2):100319. [Abstract]
- McGill University. 2025.
- bioRxiv. 2025 February 08.
- bioRxiv. 2024 August 09.
- Research Square Print. January 3rd, 2023.
- University of Siena. 2021 May.
-
Cell Proliferation/Viability Assay
-
WB
-
IF
All DNA Methyltransferase Isoforms
More
Biological Activity
|
DNMT1 |
After HCT116 colorectal carcinoma cells are treated for 6 days, a dose-dependent increase in p16expression is observed with Guadecitabine sodium (SGI-110 sodium). In addition, T24 and HCT116 cells treated with Guadecitabine sodium or 5-aza-CdR for 3 days show a dose-dependent increase in the level of p16 protein, showing the competence of Guadecitabine sodium to inhibit DNA methylation and induce p16 at both mRNA and protein levels as well as 5-aza-CdR. Thus, Guadecitabine sodium is able to inhibit DNA methylation at 5′-region and induce the expression of the p16 gene in T24 and HCT116 cells at concentrations comparable to 5-aza-CdR, and the induction of p16 expression by both agents correlates with the demethylation at the 5′-end region of the gene in both cell lines. Guadecitabine sodium is slightly less toxic than 5-aza-CdR at the doses tested up to 1 μM concentration but displaying similar toxicity at 10 μM concentration[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 929904-85-8
-
Appearance Solid
-
Molecular Weight 579.39
-
Formula C18H23N9NaO10P
-
Color White to off-white
-
SMILES
O=C1C2=C(N([C@H]3C[C@H](O)[C@@H](COP(O[C@@H]4[C@@H](CO)O[C@@H](N5C=NC(N)=NC5=O)C4)(O[Na])=O)O3)C=N2)NC(N)=N1
-
Synonyms
SGI-110 sodium; S-110 sodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
Targeting Hippo-Dependent and Hippo-Independent YAP1 Signaling for the Treatment of Childhood Rhabdomyosarcoma. [Abstract]2020 Jul 15;80(14):3046-3056. PMID: 32354737 -
Mol Cell
2022 Oct 20;82(20):3901-3918.e7. PMID: 36206767 -
J Exp Clin Cancer Res
Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells. [Abstract]2023 Mar 18;42(1):67. PMID: 36934257
Guadecitabine sodium purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2023 Mar 18;42(1):67. [Abstract]
Guadecitabine (1mg/kg; s.c.; single daily for 13 consecutive days) significantly decreases mean tumor volume of mice.
-
J Transl Med
Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches. [Abstract]2024 Mar 1;22(1):223. PMID: 38429759 -
Neoplasia
Molecular mechanisms of Guadecitabine induced FGFR4 down regulation in alveolar rhabdomyosarcomas. [Abstract]2020 May 25;22(7):274-282. PMID: 32464274
Guadecitabine sodium purchased from MedChemExpress. Usage Cited in: Neoplasia. 2020 May 25;22(7):274-282. [Abstract]
Immunoblot of the total RH30 and RH41 cell extracts treated with the indicated concentrations of SGI-110 or DMSO (control) for 5 days, probed with antibodies against FGFR4, FOXO1, IGF-1R and MYOD1.
Guadecitabine sodium purchased from MedChemExpress. Usage Cited in: Neoplasia. 2020 May 25;22(7):274-282. [Abstract]
Immunofluorescent analysis of RH30 and RH41 cells treated with DMSO or indicated concentrations of SGI-110 for 5 days.
-
Epigenomes
Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy. [Abstract]2021 Dec 14;5(4):27. PMID: 34968251 -
JID Innov
DNA Methyltransferase Inhibition Upregulates the Costimulatory Molecule ICAM-1 and the Immunogenic Phenotype of Melanoma Cells. [Abstract]2024 Oct 16;5(2):100319. PMID: 39867570 -
-
-
-
-
Solvent & Solubility
DMSO : 100 mg/mL (172.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 25 mg/mL (43.15 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
T24 cells are plated at a low density (100 per 60-mm dish) and treated with varying concentrations of 5-aza-CdR and S-110 (0.1, 0.2, 10 μM. Colonies are allowed to form for 10 to 14 days, fixed with methanol, and stained with 10% Giemsa. The number of colonies from an untreated control plate is used to calculate the plating efficiency in percent at each concentration. Triplicate dishes are used, and error bars are represented by 1 SD of the mean[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mouse: Athymic nu/nu mice are inoculated subcutaneously in the right hind flank with 107 EJ6 bladder cancer cells. After tumors reach 0.5 cm in diameter, animals are stratified into three groups with eight animals per group to begin treatments. Doses and dosing schedules are designed so that each group received molar equivalents of either S-110 or 5-Aza-CdR. The agents are administered SQ once weekly at a dose of 12.2 mg/kg for S-110 and 5.0 mg/kg for 5-Aza-CdR for three weeks. The study includes an appropriate PBS control group. Tumor sizes by caliper and body weight measurements are taken twice weekly to monitor tumor growth inhibition and tolerability[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yoo CB, et al. Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 2007 Jul 1;67(13):6400-8. [Content Brief]
[2]. Chuang JC, et al. S-110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010 May;9(5):1443-50. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 1.7260 mL | 8.6298 mL | 17.2595 mL | 43.1488 mL |
| 5 mM | 0.3452 mL | 1.7260 mL | 3.4519 mL | 8.6298 mL | |
| 10 mM | 0.1726 mL | 0.8630 mL | 1.7260 mL | 4.3149 mL | |
| 15 mM | 0.1151 mL | 0.5753 mL | 1.1506 mL | 2.8766 mL | |
| 20 mM | 0.0863 mL | 0.4315 mL | 0.8630 mL | 2.1574 mL | |
| 25 mM | 0.0690 mL | 0.3452 mL | 0.6904 mL | 1.7260 mL | |
| 30 mM | 0.0575 mL | 0.2877 mL | 0.5753 mL | 1.4383 mL | |
| 40 mM | 0.0431 mL | 0.2157 mL | 0.4315 mL | 1.0787 mL | |
| DMSO | 50 mM | 0.0345 mL | 0.1726 mL | 0.3452 mL | 0.8630 mL |
| 60 mM | 0.0288 mL | 0.1438 mL | 0.2877 mL | 0.7191 mL | |
| 80 mM | 0.0216 mL | 0.1079 mL | 0.2157 mL | 0.5394 mL | |
| 100 mM | 0.0173 mL | 0.0863 mL | 0.1726 mL | 0.4315 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.